Increased expression of interleukin-17 pathway genes in nonlesional skin of moderate-to-severe psoriasis vulgaris

British Journal of Dermatology

Volumn 174, Issue 1, 2016, Pages 136-145

  Chiricozzi, A ^a,b   Suarez Farinas M ^a   Fuentes Duculan, J ^a   Cueto, I ^a   Li, K ^c   Tian, S ^d   Brodmerkel, C ^c   Krueger, J G ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^d THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD8 ANTIGEN; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE B; GUSELKUMAB; INDUCIBLE T CELL COSTIMULATOR; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 22; STAT1 PROTEIN; BETA DEFENSIN; DEFB4A PROTEIN, HUMAN; INTERLEUKIN 2; LCN2 PROTEIN, HUMAN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROTEIN S 100; S100A7 PROTEIN, HUMAN;

ARTICLE; BODY SURFACE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; GENE EXPRESSION; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LEUKOCYTE; MULTICENTER STUDY (TOPIC); PATHOGENESIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SKIN DEFECT; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH22 CELL; UPREGULATION; COMPARATIVE STUDY; GENETICS; IMMUNOLOGY; META ANALYSIS; METABOLISM; PHYSIOLOGY; PSORIASIS;

BETA-DEFENSINS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-17; INTERLEUKIN-2; LIPOCALIN-2; PSORIASIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; S100 PROTEINS; SIGNAL TRANSDUCTION;

EID: 84955585737     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.14034     Document Type: Article

References (40)

1. Lowes MA, Bowcock AM, Krueger JG,. Pathogenesis and therapy of psoriasis. Nature 2007; 445: 866-73.
2. Gudjonsson JE, Krueger G,. A role for epigenetics in psoriasis: methylated cytosine-guanine sites differentiate lesional from nonlesional skin and from normal skin. J Invest Dermatol 2012; 132: 506-8.
3. Roberson EDO, Liu Y, Ryan C, et al,. A subset of methylated CpG sites differentiate psoriatic from normal skin. J Invest Dermatol 2012; 132: 583-92.
4. Zaba LC, Krueger JG, Lowes MA,. Resident and "inflammatory" dendritic cells in human skin. J Invest Dermatol 2009; 129: 302-8.
5. Nestle FO, Turka LA, Nickoloff BJ,. Characterization of dermal dendritic cells in psoriasis: autostimulation of T lymphocytes and induction of Th1 type cytokines. J Clin Invest 1994; 94: 202-9.
6. Johnson-Huang LM, McNutt NS, Krueger JG, et al,. Cytokine-producing dendritic cells in the pathogenesis of inflammatory skin diseases. J Clin Immunol 2009; 29: 247-56.
7. Lowes MA, Chamian F, Abello MV, et al,. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci U S A 2005; 102: 19057-62.
8. Lowes MA, Kikuchi T, Fuentes-Duculan J, et al,. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008; 128: 1207-11.
9. Chiricozzi A, Guttman-Yassky E, Suárez-Fariñas M, et al,. Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol 2011; 131: 677-87.
10. Caproni M, Antiga E, Melani L, et al,. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. J Clin Immunol 2009; 29: 210-14.
11. Arican O, Aral M, Sasmaz S, Ciragil P,. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005; 2005: 273-9.
12. Takahashi H, Tsuji H, Hashimoto Y, et al,. Serum cytokines and growth factor levels in Japanese patients with psoriasis. Clin Exp Dermatol 2010; 35: 645-9.
13. Suárez-Fariñas M, Li K, Fuentes-Duculan J, et al,. Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis. J Invest Dermatol 2012; 132: 2552-64.
14. Wang CQ, Suárez-Fariñas M, Nograles KE, et al,. IL-17 induces inflammation-associated gene products in blood monocytes, and treatment with ixekizumab reduces their expression in psoriasis patient blood. J Invest Dermatol 2014; 134: 2990-3.
15. Martin DA, Towne JE, Kricorian G, et al,. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol 2013; 133: 17-26.
16. Kagami S, Rizzo HL, Kurtz SE, et al,. IL-23 and IL-17A, but not IL-12 and IL-22, are required for optimal skin host defense against Candida albicans. J Immunol 2010; 185: 5453-62.
17. Chen Z, Laurence A, Lanno Y, et al,. Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc Natl Acad Sci USA 2006; 103: 8137-42.
18. Kagami S, Rizzo HL, Lee JJ, et al,. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol 2010; 130: 1373-83.
19. Fitch E, Harper E, Skorcheva I, et al,. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep 2007; 9: 461-7.
20. Lee E, Trepicchio WL, Oestreicher JL, et al,. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004; 199: 125-30.
21. Baker BS, Swain AD, Fry L, Valdimarsson H,. Epidermal T lymphocytes and HLA-DR expression in psoriasis. Br J Dermatol 1984; 110: 555-64.
22. Placek W, Haftek M, Thivolet J,. Sequence of changes in psoriatic epidermis. Immunocompetent cell redistribution precedes altered expression of keratinocyte differentiation markers. Acta Derm Venereol (Stockh) 1988; 68: 369-77.
23. Prens EP, Benne K, van Joost T, Benner R,. The autologous mixed epidermal cell-T lymphocyte reaction is elevated in psoriasis: a crucial role for epidermal HLA-DR+/CD1a) antigen-presenting cells. J Invest Dermatol 1991; 96: 880-7.
24. Davidovici BB, Sattar N, Prinz J, et al,. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 2010; 130: 1785-96.
25. Zhou X, Krueger JG, Kao MC, et al,. Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100 element oligonucleotide array. Physiol Genomics 2003; 13: 69-78.
26. Gudjonsson JE, Ding J, Li X, et al,. Global gene expression analysis reveals evidence for decreased lipid biosynthesis and increased innate immunity in uninvolved psoriatic skin. J Invest Dermatol 2009; 129: 2795-804.
27. Yao Y, Richman L, Morehouse C, et al,. Type I interferon: potential therapeutic target for psoriasis? PLoS ONE 2008; 3: e2737.
28. Tian S, Krueger JG, Li K, et al,. Meta-analysis derived (MAD) transcriptome of psoriasis defines the 'core' pathogenesis of disease. PLoS ONE 2012; 7: e44274.
29. Suárez-Fariñas M, Lowes MA, Zaba LC, et al,. Evaluation of the psoriasis transcriptome across different studies by gene set enrichment analysis (GSEA). PLoS ONE 2010; 5: e10247.
30. Sofen H, Smith S, Matheson RT, et al,. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J Allergy Clin Immunol 2014; 133: 1032-40.
31. Hänzelmann S, Castelo R, Guinney J,. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 2013; 14: 7.
32. DerSimonian R, Laird N,. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
33. Choi JK, Yu U, Kim S, Yoo OJ,. Combining multiple microarray studies and modeling interstudy variation. Bioinformatics 2003; 19: i84-90.
34. Zaba LC, Fuentes-Duculan J, Steinman RM, et al,. Normal human dermis contains distinct populations of CD11cBDCA-1 dendritic cells and CD163FXIIIA macrophages. J Clin Invest 2007; 117: 2517-25.
35. Lowes MA, Russell CB, Martin DA, et al,. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol 2013; 34: 174-81.
36. Ortega C, Fernandez AS, Carrillo JM, et al,. IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J Leukoc Biol 2009; 86: 435-43.
37. Chiricozzi A, Nograles KE, Johnson-Huang LM, et al,. IL-17 induces an expanded range of downstream genes in reconstituted human epidermis model. PLoS ONE 2014; 9: e90284.
38. Gudjonsson JE, Ding J, Johnston A, et al,. Assessment of the psoriatic transcriptome in a large sample: additional regulated genes and comparisons with in vitro models. J Invest Dermatol 2010; 130: 1829-40.
39. Swindell WR, Johnston A, Voorhees JJ, et al,. Dissecting the psoriasis transcriptome: inflammatory- and cytokine-driven gene expression in lesions from 163 patients. BMC Genom 2013; 14: 527.
40. Jabbari A, Suárez-Fariñas M, Dewell S, et al,. Transcriptional profiling of psoriasis using RNA-seq reveals previously unidentified differentially expressed genes. J Invest Dermatol 2012; 132: 246-9.